Alzheimer's. AIFA first plenary meeting of centers participating in the project "Interceptor"

The study project which aims to identify the "marker" or "set of markers" capable of accurately predicting the conversion of the diagnosis of mild cognitive impairment (MCI) into a disease of the disease. Alzheimer's, after 2 or 3 years of follow-up, in order to identify patients who will benefit from new therapies currently being tested

30 JUL – It happened today at the # Italiana del Farmaco Agency the first plenary meeting of the centers participating in "Iterceptor", a study project aimed at identifying the "marker" or "set of markers" capable of accurately predicting the conversion of the diagnosis of decline Insufficiency cognitive impairment (MCI) in Alzheimer's disease, after 2 or 3 years of follow-up, to identify patients who, appropriately, may benefit from new therapies tested

Attended the meeting representatives Coordinating Committee, the four expert knowledge centers for the reading of certain biomarkers and 20 centers for cognitive disorders and dementia (CDCD) in which they will be recruited patients.

The project, which is sponsored by the Institute of Neurology of the University Polyclinic Foundation "A. Gemelli" – Catholic University of the Sacred Heart of Rome, has a strategic character and is funded by the AIFA through the use of funds transferred to the "Extraordinary Reserve for Institutional Activity of the IAAF".

July 30, 2018
© All rights reserved

Other articles in Science and Drugs